FibroGen Inc

NASDAQ:FGEN  
12.98
+0.14 (+1.09%)
Products, Strategic Combinations

Fibrogen And HiFiBiO Announce Partnership To Advance Therapies For Cancer And Autoimmune Disease

Published: 06/17/2021 11:44 GMT
FibroGen Inc (FGEN) - Fibrogen and Hifibio Announce Transformative Partnership to Advance Next-generation Therapies for Patients With Cancer and Autoimmune Disease.
Fibrogen - Hifibio to Receive $25 Million Upfront, and Up to a Total of $1.1b in Additional Milestone Payments Across All Three Programs, Plus Royalties.
Fibrogen Inc - Fibrogen Exclusively Licenses Hifibio's Galectin-9 Program, and Obtains an Exclusive Option to Their Cxcr5 and Ccr8 Programs.
Fibrogen Inc - Lead Product Candidates From Cxcr5 and Ccr8 Programs Are Expected to Enter Clinical Development by Middle of 2023.